We offer a new solution to treat cartilage lesions. Indeed, once damaged, cartilage has a very limited capacity for self-repair and, if left untreated, often evolves into osteoarthritis, the most common joint disorder.
We have developed and recently patented a method for the production of Cartibeads™, which are the first high-quality hyaline cartilage microtissues resembling native articular cartilage. This innovative product aims to regenerate cartilage damage and targets focal lesions and early osteoarthritis.
Preclinical data have demonstrated the safety and efficacy of Cartibeads™ in the treatment of focal knee injuries. We are now ready for the first-in man study planned for 2021: patient recruitment at the University Hospitals of Geneva and Clinique la Colline, Hirslanden Group, Geneva, Switzerland.